These are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information. For more information, please see our FAQs.
2 files

Expedient Method for Direct Mono-amidation of Phosphonic and Phosphoric Acids

submitted on 03.04.2020, 06:28 and posted on 06.04.2020, 07:14 by Victoria Yan, Cong-Dat Pham, Florian Muller
Mono-amidated P(V) pro-drugs predominately contribute to the vastly improved delivery of phosphate and phosphonate-containing anti-viral/cancer nucleotide analogues. However, synthetic approaches towards their formation are often harsh and unreliable, which may hamper the identification of novel, more effective amine pro-drugs. Here, we show that direct mono-amidation of structurally complex phosphonic and phosphoric acids may be accomplished in as quickly as seconds by re-purposing the PPh3/DIAD redox pair. Where the triphenylphosphine oxide byproduct is often cited as a vulnerability, we use its formation as an asset. Juxtaposing the anionic nature of the generated mono-amidated product, the desired product may be isolated with a single water extraction. Compared to state-of-the-art strategies towards phosphoramidates, our approach is mild, reliable, and enables access to a variety of aliphatic and benzylic amines for pro-drug attachment.


American Cancer Society

National Comprehensive Cancer Network


Email Address of Submitting Author


University of Texas MD Anderson Cancer Center



ORCID For Submitting Author


Declaration of Conflict of Interest

V.C.Y., C.D.P., and F.L.M. are inventors on a patent application describing a novel method for the mono-amidation of phosphate- and phosphonate-containing drugs.